FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Kim Brøsen

Research Profile

Chemicals & Drugs

Physiology

Phenomena

Oxidation-Reduction

Procedures

Geographic Areas

Denmark

Co-author Network

Publications

TOP 3
Kim Brøsen
BCPT Nordic Prize in Basic and Clinical Pharmacology and Toxicology for 2012 to Michael J. Mulvany.
Tore B Stage; Henning Beck-Nielsen; Mette M H Christensen; Søren Feddersen; Kim Brøsen
The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARγ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes.
Kim Brøsen
Letter from the editor.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Kim Brøsen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Kim Brøsen
BCPT Nordic Prize in Basic and Clinical Pharmacology and Toxicology for 2012 to Michael J. Mulvany.
Basic & clinical pharmacology & toxicology 2013;112(5):287-8.
2013: Tore B Stage; Henning Beck-Nielsen; Mette M H Christensen; Søren Feddersen; Kim Brøsen
The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARγ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes.
Pharmacogenetics and genomics 2013;23(4):219-27.
2013: Kim Brøsen
Letter from the editor.
Basic & clinical pharmacology & toxicology 2013;112(1):1.
2012: Kim Brøsen
Letter from the editor.
Basic & clinical pharmacology & toxicology 2012;111(6):361.
2012: Rasmus Steen Pedersen; Mette Marie Hougaard Christensen; Kim Brøsen
Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population.
European journal of clinical pharmacology 2012;68(10):1463-4.
2012: Kim Brøsen
BCPT Nordic Prize in Basic & Clinical Pharmacology & Toxicology for 2011 to Pertti J. Neuvonen.
Basic & clinical pharmacology & toxicology 2012;110(3):205-6.
2011: Charlotte Brasch-Andersen; Kim Brøsen; Lene Christiansen; Malik U Møller; Marit Otto; Mikael Thinggaard; Søren H Sindrup
A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C).
European journal of clinical pharmacology 2011;67(11):1131-7.
2011: Kim Brøsen
[Drug induced hepatotoxicity--don't forget herbals and dietary supplements!].
Ugeskrift for laeger 2011;173(34):2028.
2011: Kim Brøsen
Letter from the editor.
Basic & clinical pharmacology & toxicology 2011;108(1):1.
2010: Mia Birkhøj Kjærstad; Flemming Nielsen; Lene Nøhr-Jensen; Stine Zwisler; Kim Brøsen; Helle Raun Andersen
Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women.
European journal of clinical pharmacology 2010;66(12):1189-97.
2010: Rasmus Steen Pedersen; Charlotte Brasch-Andersen; Sarah C Sim; Troels K Bergmann; Jónrit Halling; Maria Skaalum Petersen; Pál Weihe; Hege Edvardsen; Vessela N Kristensen; Kim Brøsen; Magnus Ingelman-Sundberg
Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations.
European journal of clinical pharmacology 2010;66(12):1199-205.
2010: Donald Birkett; Kim Brøsen; Ingolf Cascorbi; Lars L Gustafsson; Simon Maxwell; Lembit Rago; Michael Rawlins; Marcus Reidenberg; Folke Sjöqvist; Tony Smith; Petra Thuerman; Andrew Walubo; Michael Orme; Folke Sjöqvist
Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology.
Basic & clinical pharmacology & toxicology 2010;107(1):531-59.
2009: Kim Brøsen
Letter from the editor.
Basic & clinical pharmacology & toxicology 2009;104(1):1-2.
2008: Marit Otto; Flemming W Bach; Troels S Jensen; Kim Brøsen; Søren H Sindrup
Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial.
Pain 2008;139(2):275-83.
2008: Werner Vach; Troels K Bergmann; Kim Brøsen
No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(11):1903-4; author reply 1904-5.
2008: Peer Tfelt-Hansen; Kim Brøsen
Pharmacogenomics and migraine: possible implications.
The journal of headache and pain 2008;9(1):13-8.
2008: Lene Sorensen; Bent Nielsen; Kurt B Stage; Kim Brøsen; Per Damkier
Implementation of a rational pharmacotherapy intervention for inpatients at a psychiatric department.
Nordic journal of psychiatry 2008;62(3):242-9.
2007: Maria Skaalum Petersen; Jónrit Halling; Per Damkier; Flemming Nielsen; Philippe Grandjean; Pál Weihe; Kim Brøsen
Polychlorinated biphenyl (PCB) induction of CYP3A4 enzyme activity in healthy Faroese adults.
Toxicology and applied pharmacology 2007;224(2):202-6.
2007: Kim Brøsen
[Sex differences in pharmacology].
Ugeskrift for laeger 2007;169(25):2408-11.
2007: Astrid-Helene Andreasen; Kim Brøsen; Per Damkier
A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4.
Epilepsia 2007;48(3):490-6.
2006: Maria Skaalum Petersen; Jónrit Halling; Per Damkier; Flemming Nielsen; Philippe Grandjean; Pál Weihe; Kim Brøsen
Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls.
European journal of clinical pharmacology 2006;62(12):1041-8.
2006: Rasmus Steen Pedersen; Per Damkier; Kim Brøsen
Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers.
European journal of clinical pharmacology 2006;62(7):513-21.
2006: Tanja Busk Bidstrup; Per Damkier; Aage Kristian Olsen; Marianne Ekblom; Anders Karlsson; Kim Brøsen
The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.
British journal of clinical pharmacology 2006;61(1):49-57.
2006: Thomas P Enggaard; Lars Poulsen; Lars Arendt-Nielsen; Kim Brøsen; Joachim Ossig; Søren H Sindrup
The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6.
Anesthesia and analgesia 2006;102(1):146-50.
2005: John Teilmann Larsen; Kim Brøsen
Consumption of charcoal-broiled meat as an experimental tool for discerning CYP1A2-mediated drug metabolism in vivo.
Basic & clinical pharmacology & toxicology 2005;97(3):141-8.
2005: Jónrit Halling; Maria Skaalum Petersen; Per Damkier; Flemming Nielsen; Philippe Grandjean; Pál Weihe; Stefan Lundgren; Mia Sandberg Lundblad; Kim Brøsen
Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
European journal of clinical pharmacology 2005;61(7):491-7.
2005: Hanne Madsen; Kim Brøsen; Niels Frimodt-Møller; Bente Gahrn-Hansen
[Antibiotics and overweight].
Ugeskrift for laeger 2005;167(21):2266-70.
2005: Kim Brøsen
[Classical pharmacogenetics].
Ugeskrift for laeger 2005;167(20):2143-6.
2005: S Laugesen; Thomas P Enggaard; Rasmus Steen Pedersen; Søren H Sindrup; Kim Brøsen
Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol.
Clinical pharmacology and therapeutics 2005;77(4):312-23.
2004: Tanja Busk Bidstrup; Nicolaj Stilling; Per Damkier; Birgitte Scharling; Mikael Søndergård Thomsen; Kim Brøsen
Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide.
European journal of clinical pharmacology 2004;60(2):109-14.
2004: Jens P Kampmann; Kim Brøsen; Per Buch Andreasen
[Clinical pharmacology--important events in 2003. The Danish Society of Clinical Pharmacology].
Ugeskrift for laeger 2004;166(12):1110.
2004: Rasmus Steen Pedersen; Céline Verstuyft; Laurent Becquemont; Patrice Jaillon; Kim Brøsen
Cytochrome P4502C9 (CYP2C9) genotypes in a Nordic population in Denmark.
Basic & clinical pharmacology & toxicology 2004;94(3):151-2.
2004: Ulrik S Justesen; A B Andersen; Niels A Klitgaard; Kim Brøsen; Jan Gerstoft; Court Pedersen
Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;38(3):426-9.
2004: Kim Brøsen
Some aspects of genetic polymorphism in the biotransformation of antidepressants.
Thérapie 2004;59(1):5-12.
2003: Vibeke M Breinholt; Salka E Rasmussen; Kim Brøsen; Thomas H Friedberg
In vitro metabolism of genistein and tangeretin by human and murine cytochrome P450s.
Pharmacology & toxicology 2003;93(1):14-22.
2002: Palle Mark Christensen; Kim Brøsen; Kim Brixen; Ivar Sønbø Kristiansen
Expressing effects of osteoporosis interventions in terms of postponing of fractures.
European journal of clinical pharmacology 2002;58(9):629-33.
2002: Birgitte B Rasmussen; Thomas Brix; Kirsten Ohm Kyvik; Kim Brøsen
The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors.
Pharmacogenetics 2002;12(6):473-8.
2002: Vibeke M Breinholt; E A Offord; C Brouwer; Salka E Nielsen; Kim Brøsen; T Friedberg
In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2002;40(5):609-16.
2002: Gesche Jürgens; Hanne Rolighed Christensen; Kim Brøsen; Jesper Sonne; Steffen Loft; Niels Vidiendal Olsen
Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans.
Clinical pharmacology and therapeutics 2002;71(4):214-20.
2002: Henrik E Poulsen; Ole E Schmitz; Kim Brøsen
[Clinical pharmacology 2001--important events. The Danish Society of Clinical Pharmacology].
Ugeskrift for laeger 2002;164(12):1652.
2002: Palle Mark Christensen; Kim Brøsen; Kim Brixen; Henning Beck-Nielsen; Jes Søgaard; Ivar Sønbø Kristiansen
[Pharmaco-economic evaluation of drug therapy osteoporosis. A literature review].
Ugeskrift for laeger 2002;164(10):1339-45.
2002: Gesche Jürgens; Kai Henrik Wiborg Lange; Lene Ørskov Reuther; Birgitte Buur Rasmussen; Kim Brøsen; Hanne Rolighed Christensen
Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men.
Clinical pharmacology and therapeutics 2002;71(3):162-8.
2001: Selim Kortunay; Atila Bozkurt; Nursabah E Basci; Kim Brøsen; S Oguz Kayaalp
Dose-dependent inhibition of the CYP2D6 catalyzed oxidation of sparteine by mepyramine in healthy volunteers.
Pharmacology & toxicology 2001;89(6):331-4.
2001: Julia Kirchheiner; Kim Brøsen; Marja-Liisa Dahl; LF Gram; S Kasper; Ivar Roots; Folke Sjöqvist; Edoardo Spina; Jürgen Brockmöller
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.
Acta psychiatrica Scandinavica 2001;104(3):173-92.
2001: Kim Brøsen; C A Naranjo
Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2001;11(4):275-83.
2001: John Teilmann Larsen; S V Clemensen; Niels A Klitgaard; Bent Nielsen; Kim Brøsen
[Clozapine-induced toxic hepatitis].
Ugeskrift for laeger 2001;163(14):2013-4.
2001: John Larsen; A Arnberg; Kim Brøsen
[Tramadol and oxazepam. Effect on pulmonry function in elderly patients with chronic obstructive lung disease].
Ugeskrift for laeger 2001;163(4):458-60.
2001: H Madsen; Thomas P Enggaard; LL Hansen; Niels A Klitgaard; Kim Brøsen
Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
Clinical pharmacology and therapeutics 2001;69(1):41-7.
2000: Palle Mark Christensen; U Hedegaard; Kim Brøsen
[Treatment of pinworm in the first trimester].
Ugeskrift for laeger 2000;162(48):6552.
2000: Ulrik S Justesen; Kim Brøsen; Court Pedersen
[HIV protease inhibitors and interactions].
Ugeskrift for laeger 2000;162(35):4677-81.
2000: Per Damkier; Kim Brøsen
Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.
Clinical pharmacology and therapeutics 2000;68(2):199-209.
2000: B B Rasmussen; Kim Brøsen
Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
Therapeutic drug monitoring 2000;22(2):143-54.
1999: Per Damkier; LL Hansen; Kim Brøsen
Rifampicin treatment greatly increases the apparent oral clearance of quinidine.
Pharmacology & toxicology 1999;85(6):257-62.
1999: B Buur-Rasmussen; Kim Brøsen
Cytochrome P450 and therapeutic drug monitoring with respect to clozapine.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 1999;9(6):453-9.
1999: Søren H Sindrup; C Madsen; Kim Brøsen; Troels S Jensen
The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels.
Clinical pharmacology and therapeutics 1999;66(6):636-41.
1999: LL Hansen; Kim Brøsen
Quantitative determination of tolbutamide and its metabolites in human plasma and urine by high-performance liquid chromatography and UV detection.
Therapeutic drug monitoring 1999;21(6):664-71.
1999: Søren H Sindrup; G Andersen; C Madsen; T Smith; Kim Brøsen; Troels S Jensen
Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial.
Pain 1999;83(1):85-90.
1999: Lise Bathum; Erik Frandsen Skjelbo; T K Mutabingwa; H Madsen; Mogens Hørder; Kim Brøsen
Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
British journal of clinical pharmacology 1999;48(3):395-401.
1999: Per Damkier; LL Hansen; Kim Brøsen
Effect of fluvoxamine on the pharmacokinetics of quinidine.
European journal of clinical pharmacology 1999;55(6):451-6.
1999: John Teilmann Larsen; LL Hansen; O Spigset; Kim Brøsen
Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo.
European journal of clinical pharmacology 1999;55(5):375-82.
1999: Selim Kortunay; Atila Bozkurt; Lise Bathum; Nursabah E Basci; Meral Calgüneri; Kim Brøsen; S Oguz Kayaalp
CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus.
Annals of the rheumatic diseases 1999;58(3):182-5.
1999: Selim Kortunay; Atila Bozkurt; Lise Bathum; Nursabah E Basci; Meral Calgüneri; Kim Brøsen; S Oguz Kayaalp
CYP2D6 polymorphism in systemic lupus erythematosus patients.
European journal of clinical pharmacology 1999;55(1):21-5.
1999: L Fjordside; UE Jeppesen; C B Eap; K Powell; P Baumann; Kim Brøsen
The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.
Pharmacogenetics 1999;9(1):55-60.
1998: Palle Mark Christensen; P C Gøtzsche; Kim Brøsen
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.
Pharmacogenetics 1998;8(6):473-9.
1998: BB Rasmussen; TL Nielsen; Kim Brøsen
Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro.
Pharmacology & toxicology 1998;83(6):240-5.
1998: BB Rasmussen; TL Nielsen; Kim Brøsen
Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.
European journal of clinical pharmacology 1998;54(9-10):735-40.
1998: Kim Brøsen
Differences in interactions of SSRIs.
International clinical psychopharmacology 1998;13 Suppl 5():S45-7.
1998: LL Hansen; John Teilmann Larsen; Kim Brøsen
Determination of tacrine and its metabolites in human plasma and urine by high-performance liquid chromatography and fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;712(1-2):183-91.
1998: Lars Poulsen; L Riishede; Kim Brøsen; S Clemensen; Søren H Sindrup
Codeine in post-operative pain. Study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide.
European journal of clinical pharmacology 1998;54(6):451-4.
1998: Lise Bathum; Karen Andersen-Ranberg; Jesper L Boldsen; Kim Brøsen; Bernard Jeune
Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevitY. Role of CYP2D6 and CYP2C19 in longevity.
European journal of clinical pharmacology 1998;54(5):427-30.
1998: M Andersen; A Arnberg; Kim Brøsen; LF Gram; Kamilla Buchberg Petersen
[Drug information center at the Center for Clinical Pharmacology in Odense].
Ugeskrift for laeger 1998;160(22):3234.
1998: Lise Bathum; I Johansson; M Ingelman-Sundberg; Mogens Hørder; Kim Brøsen
Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Pharmacogenetics 1998;8(2):119-23.
1998: Lise Bathum; Thomas S Hansen; Mogens Hørder; Kim Brøsen
A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry.
Therapeutic drug monitoring 1998;20(1):1-6.
1998: Søren H Sindrup; Kim Brøsen
[Combination preparations of codeine and paracetamol].
Ugeskrift for laeger 1998;160(4):448-9.
1997: UE Jeppesen; BB Rasmussen; Kim Brøsen
Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide.
Clinical pharmacology and therapeutics 1997;62(3):279-86.
1997: H Madsen; Jens Møller Rasmussen; Kim Brøsen
Interaction between tramadol and phenprocoumon.
Lancet 1997;350(9078):637.
1997: BB Rasmussen; Kim Brøsen
Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
British journal of clinical pharmacology 1997;43(3):253-8.
1997: H Madsen; BB Rasmussen; Kim Brøsen
Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4.
Clinical pharmacology and therapeutics 1997;61(3):319-24.
1997: BB Rasmussen; UE Jeppesen; David Gaist; Kim Brøsen
Griseofulvin and fluvoxamine interactions with the metabolism of theophylline.
Therapeutic drug monitoring 1997;19(1):56-62.
1997: UE Jeppesen; Jens Møller Rasmussen; Kim Brøsen
Clinically important interaction between azathioprine (Imurel) and phenprocoumon (Marcoumar)
European journal of clinical pharmacology 1997;52(6):503-4.
1997: Palle Mark Christensen; P C Gøtzsche; Kim Brøsen
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
European journal of clinical pharmacology 1997;51(5):389-93.
1996: H Madsen; T S Hansen; Kim Brøsen
Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.
Pharmacogenetics 1996;6(6):513-9.
1996: L Poulsen; Lars Arendt-Nielsen; Kim Brøsen; Søren H Sindrup
The hypoalgesic effect of tramadol in relation to CYP2D6.
Clinical pharmacology and therapeutics 1996;60(6):636-44.
1996: Kim Brøsen
Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry.
Therapeutic drug monitoring 1996;18(4):393-6.
1996: BB Rasmussen; Kim Brøsen
Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.
Therapeutic drug monitoring 1996;18(3):254-62.
1996: K K Nielsen; J P Flinois; P Beaune; Kim Brøsen
The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways.
The Journal of pharmacology and experimental therapeutics 1996;277(3):1659-64.
1996: Kim Brøsen
Are pharmacokinetic drug interactions with the SSRIs an issue?
International clinical psychopharmacology 1996;11 Suppl 1():23-7.
1996: BB Rasmussen; Kim Brøsen
Determination of theophylline and its metabolites in human urine and plasma by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1996;676(1):169-74.
1996: L Poulsen; Kim Brøsen; Lars Arendt-Nielsen; Lars F Gram; K Elbaek; Søren H Sindrup
Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.
European journal of clinical pharmacology 1996;51(3-4):289-95.
1996: UE Jeppesen; Lars F Gram; K Vistisen; S Loft; H E Poulsen; Kim Brøsen
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
European journal of clinical pharmacology 1996;51(1):73-8.
1996: Kim Brøsen; E Skjelbo; K K Nielsen
Imipramine: a model drug for P450 research.
Methods in enzymology 1996;272():177-86.
1996: Søren H Sindrup; U Hofmann; J Asmussen; Gerd Mikus; Kim Brøsen; F Nielsen; S H Ingwersen; C Broen Christensen
Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake.
European journal of clinical pharmacology 1996;49(6):503-9.
1995: Søren H Sindrup; Kim Brøsen
The pharmacogenetics of codeine hypoalgesia.
Pharmacogenetics 1995;5(6):335-46.
1995: Kim Brøsen; S M de Morais; U A Meyer; J A Goldstein
A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
Pharmacogenetics 1995;5(5):312-7.
1995: Lars F Gram; T W Guentert; S Grange; K Vistisen; Kim Brøsen
Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study.
Clinical pharmacology and therapeutics 1995;57(6):670-7.
1995: H Madsen; K K Nielsen; Kim Brøsen
Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
British journal of clinical pharmacology 1995;39(4):433-9.
1995: L Poulsen; Lars Arendt-Nielsen; Kim Brøsen; K K Nielsen; Lars F Gram; Søren H Sindrup
The hypoalgesic effect of imipramine in different human experimental pain models.
Pain 1995;60(3):287-93.
1995: BB Rasmussen; J Maënpää; Olavi Pelkonen; S Loft; H E Poulsen; J Lykkesfeldt; Kim Brøsen
Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine.
British journal of clinical pharmacology 1995;39(2):151-9.
1995: Kim Brøsen
Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2.
Clinical pharmacokinetics 1995;29 Suppl 1():20-5.
1995: F Nielsen; Jens-Ulrik Rosholm; Kim Brøsen
Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.
European journal of clinical pharmacology 1995;48(6):501-4.
1994: F Nielsen; K K Nielsen; Kim Brøsen
Determination of quinidine, dihydroquinidine, (3S)-3-hydroxyquinidine and quinidine N-oxide in plasma and urine by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1994;660(1):103-10.
1994: K K Nielsen; Kim Brøsen; M G Hansen; Lars F Gram
Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
Clinical pharmacology and therapeutics 1994;55(5):518-27.
1994: Kim Brøsen; P N Nielsen; Klaus Brusgaard; Lars F Gram; K Skjødt
CYP2D6 genotype determination in the Danish population.
European journal of clinical pharmacology 1994;47(3):221-5.
1994: K K Nielsen; Kim Brøsen; M G Hansen; Lars F Gram
Glucuronidation clearance of 8-hydroxyclomipramine in relation to sparteine and mephenytoin phenotype.
European journal of clinical pharmacology 1994;47(2):209-10.
1993: Kim Brøsen
The pharmacogenetics of the selective serotonin reuptake inhibitors.
The Clinical investigator 1993;71(12):1002-9.
1993: Kim Brøsen; E Skjelbo; H Flachs
Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.
British journal of clinical pharmacology 1993;36(2):105-8.
1993: Søren H Sindrup; L Poulsen; Kim Brøsen; Lars Arendt-Nielsen; Lars F Gram
Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?
Pain 1993;53(3):335-9.
1993: Kim Brøsen; Per Kragh-Sørensen
Concomitant intake of nortriptyline and carbamazepine.
Therapeutic drug monitoring 1993;15(3):258-60.
1993: Lars F Gram; Kim Brøsen
Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.
British journal of clinical pharmacology 1993;35(6):649-52.
1993: K K Nielsen; Kim Brøsen
High-performance liquid chromatography of clomipramine and metabolites in human plasma and urine.
Therapeutic drug monitoring 1993;15(2):122-8.
1993: Kim Brøsen; E Skjelbo; BB Rasmussen; H E Poulsen; S Loft
Fluvoxamine is a potent inhibitor of cytochrome P4501A2.
Biochemical pharmacology 1993;45(6):1211-4.
1993: Lars F Gram; M G Hansen; Søren H Sindrup; Kim Brøsen; J H Poulsen; T Aaes-Jørgensen; K F Overø
Citalopram: interaction studies with levomepromazine, imipramine, and lithium.
Therapeutic drug monitoring 1993;15(1):18-24.
1993: Søren H Sindrup; Kim Brøsen; M G Hansen; T Aaes-Jørgensen; K F Overø; Lars F Gram
Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
Therapeutic drug monitoring 1993;15(1):11-7.
1993: K K Nielsen; Kim Brøsen
High-performance liquid chromatography of imipramine and six metabolites in human plasma and urine.
Journal of chromatography 1993;612(1):87-94.
1993: Kim Brøsen; J G Hansen; K K Nielsen; Søren H Sindrup; Lars F Gram
Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.
European journal of clinical pharmacology 1993;44(4):349-55.
1993: Kim Brøsen; Søren H Sindrup; E Skjelbo; K K Nielsen; Lars F Gram
Role of genetic polymorphism in psychopharmacology--an update.
Psychopharmacology series 1993;10():199-211.
1992: Søren H Sindrup; U Bjerre; A Dejgaard; Kim Brøsen; T Aaes-Jørgensen; Lars F Gram
The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy.
Clinical pharmacology and therapeutics 1992;52(5):547-52.
1992: E Skjelbo; Kim Brøsen
Inhibitors of imipramine metabolism by human liver microsomes.
British journal of clinical pharmacology 1992;34(3):256-61.
1992: Søren H Sindrup; Kim Brøsen; Lars F Gram
Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
Clinical pharmacology and therapeutics 1992;51(3):288-95.
1992: Søren H Sindrup; Kim Brøsen; Lars F Gram; Jesper Hallas; E Skjelbo; A Allen; G D Allen; S M Cooper; G Mellows; T C Tasker
The relationship between paroxetine and the sparteine oxidation polymorphism.
Clinical pharmacology and therapeutics 1992;51(3):278-87.
1992: Søren H Sindrup; Lars Arendt-Nielsen; Kim Brøsen; Peter Bjerring; H R Angelo; B Eriksen; Lars F Gram
The effect of quinidine on the analgesic effect of codeine.
European journal of clinical pharmacology 1992;42(6):587-91.
1992: Jesper Hallas; Lars F Gram; E Grodum; N Damsbo; Kim Brøsen; T Haghfelt; B Harvald; J Beck-Nielsen; J Worm; K B Jensen
Drug related admissions to medical wards: a population based survey.
British journal of clinical pharmacology 1992;33(1):61-8.
1992: Kim Brøsen; Lars F Gram; Søren H Sindrup; E Skjelbo; K K Nielsen
Pharmacogenetics of tricyclic and novel antidepressants: recent developments.
Clinical neuropharmacology 1992;15 Suppl 1 Pt A():80A-81A.
1992: Lars F Gram; Kim Brøsen; Søren H Sindrup; E Skjelbo; K K Nielsen
Pharmacogenetics in psychopharmacology: basic principles and clinical implications.
Clinical neuropharmacology 1992;15 Suppl 1 Pt A():76A-77A.
1992: Lars F Gram; Kim Brøsen
Drug interactions and pharmacokinetic risk factors when using antidepressants in the medically ill patients.
Clinical neuropharmacology 1992;15 Suppl 1 Pt A():642A-643A.
1992: Søren H Sindrup; Kim Brøsen; Lars F Gram
Antidepressants in pain treatment: antidepressant or analgesic effect?
Clinical neuropharmacology 1992;15 Suppl 1 Pt A():636A-637A.
1992: Søren H Sindrup; Kim Brøsen; Lars F Gram
The mechanism of action of antidepressants in pain treatment: controlled cross-over studies in diabetic neuropathy.
Clinical neuropharmacology 1992;15 Suppl 1 Pt A():380A-381A.
1992: K K Nielsen; Kim Brøsen; Lars F Gram
Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.
European journal of clinical pharmacology 1992;43(4):405-11.
1992: Søren H Sindrup; C Tuxen; Lars F Gram; E Grodum; T Skjold; Kim Brøsen; H Beck-Nielsen
Lack of effect of mianserin on the symptoms of diabetic neuropathy.
European journal of clinical pharmacology 1992;43(3):251-5.
1991: Jesper Hallas; J Worm; J Beck-Nielsen; Lars F Gram; E Grodum; N Damsbo; Kim Brøsen
Drug related events and drug utilization in patients admitted to a geriatric hospital department.
Danish medical bulletin 1991;38(5):417-20.
1991: K Clasen; L Madsen; Kim Brøsen; K Albøge; S Misfeldt; Lars F Gram
Sparteine and mephenytoin oxidation: genetic polymorphisms in east and west Greenland.
Clinical pharmacology and therapeutics 1991;49(6):624-31.
1991: Kim Brøsen; Lars F Gram; Per Kragh-Sørensen
Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
Therapeutic drug monitoring 1991;13(2):177-82.
1991: J Jensen; L H Nielsen; N Lyhne; Jesper Hallas; Kim Brøsen; Lars F Gram
Drugs and femoral neck fracture: a case-control study.
Journal of internal medicine 1991;229(1):29-33.
1991: E Skjelbo; Kim Brøsen; Jesper Hallas; Lars F Gram
The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
Clinical pharmacology and therapeutics 1991;49(1):18-23.
1990: Søren H Sindrup; Kim Brøsen; Peter Bjerring; Lars Arendt-Nielsen; U Larsen; H R Angelo; Lars F Gram
Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine.
Clinical pharmacology and therapeutics 1990;48(6):686-93.
1990: Søren H Sindrup; Lars F Gram; T Skjold; E Grodum; Kim Brøsen; H Beck-Nielsen
Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study.
British journal of clinical pharmacology 1990;30(5):683-91.
1990: Søren H Sindrup; Kim Brøsen; Lars F Gram
Nonlinear kinetics of imipramine in low and medium plasma level ranges.
Therapeutic drug monitoring 1990;12(5):445-9.
1990: Jesper Hallas; B Harvald; Lars F Gram; E Grodum; Kim Brøsen; T Haghfelt; N Damsbo
Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention.
Journal of internal medicine 1990;228(2):83-90.
1990: Søren H Sindrup; Lars F Gram; Kim Brøsen; O Eshøj; E F Mogensen
The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms.
Pain 1990;42(2):135-44.
1990: M D Nielsen; Kim Brøsen; Lars F Gram
A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.
British journal of clinical pharmacology 1990;29(3):299-304.
1990: Kim Brøsen; F Davidsen; Lars F Gram
Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.
British journal of clinical pharmacology 1990;29(2):248-53.
1989: Lars F Gram; Kim Brøsen; Per Kragh-Sørensen; P Christensen
Steady-state plasma levels of E- and Z-10-OH-nortriptyline in nortriptyline-treated patients: significance of concurrent medication and the sparteine oxidation phenotype.
Therapeutic drug monitoring 1989;11(5):508-14.
1989: A Drøhse; L Bathum; Kim Brøsen; Lars F Gram
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
British journal of clinical pharmacology 1989;27(5):620-5.
1989: Kim Brøsen; Lars F Gram
Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
European journal of clinical pharmacology 1989;37(2):155-60.
1989: Kim Brøsen; Lars F Gram
Pharmacokinetic and clinical significance of genetic variability in psychotropic drug metabolism.
Psychopharmacology series 1989;7():192-200.
1989: Lars F Gram; Kim Brøsen
Inhibitors of the microsomal oxidation of psychotropic drugs: selectivity and clinical significance.
Psychopharmacology series 1989;7():172-80.
1989: Kim Brøsen; Lars F Gram
Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
European journal of clinical pharmacology 1989;36(6):537-47.
1988: Kim Brøsen
The relationship between imipramine metabolism and the sparteine oxidation polymorphism.
Danish medical bulletin 1988;35(5):460-8.
1988: Kim Brøsen; Lars F Gram
First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
Clinical pharmacology and therapeutics 1988;43(4):400-6.
1988: F Davidsen; T Haghfelt; Lars F Gram; Kim Brøsen
Adverse drug reactions and drug non-compliance as primary causes of admission to a cardiology department.
European journal of clinical pharmacology 1988;34(1):83-6.